2021-04-23 08:30
Biovica, active in cancer diagnostics, today announced that the results from a budget impact model of monitoring with DiviTum®TKa can give savings of up to three times the extra spend relative to current management. The results will be presented at...
2021-03-18 08:00 Regulatory Interim
FDA resumes review of DiviTum®TKa submission Significant events during the third quarter Significant events after the end of the period Audiocast: When: 18 March 2021 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2020-2021...
2021-03-11 11:10 Regulatory
Biovica, active in cancer diagnostics, today announced that the results from the breast cancer study PROMIX at Karolinska University Hospital is published in the scientific journal ESMO Open. The study showed that testing for TKa levels during early treatment...
2021-02-26 08:00 Regulatory
The Nomination Committee prior to the 2021 Annual General Meeting will consist of three members, who shall represent the two shareholders with the most number of shares who accept the assignment to be part of the Nomination Committee as of December 31...
2021-01-29 20:20 Regulatory
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has resumed its review of Biovica’s 510(k)-submission for DiviTum®TKa. “This is fantastic news on our journey to make the test available...
2021-01-18 08:00
DiviTum®TKa has been selected to be included in the new prospective clinical study TIRESIAS, with the aim of investigating if DiviTum®TKa can be used to identify early resistance to treatment by a CDK4/6 inhibitor in combination with an aromatase...
2021-01-16 12:48 Regulatory
Biovica, active in cancer diagnostics, today announced that the US Food and Drug Administration (FDA) has indicated that its previously communicated reallocation of resources to address COVID-19 continues to impact the timeline for completion of the review...
2021-01-12 11:50
Biovica's CEO and main shareholder Anders Rylander has, to facilitate the administration of the company's warrant program 3, lent 127,000 shares to Pareto Securities AB. The program comprises 200,000 options, of which 145,000 options have been...
2020-12-03 08:00 Regulatory Interim
Convincing study results and application submitted to the FDA - commercialization just around the corner Significant events during the second quarter · Clinical validation, which is the last step required for the FDA application, has been completed...
2020-11-23 08:00
DiviTum®TKa has been selected to be included in a new prospective study of women with hormone receptor positive metastatic breast cancer. The aim of including DiviTum®TKa in the study is to investigate if this marker can be used for disease monitoring...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No